Previous 10 | Next 10 |
The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...
Positive results achieved from the phase 3 MAESTRO-NAFLD-1 study using resmetirom to treat patients with NASH. Nearly half of patients in 100 mg dose arm achieved 50% reduction liver fat. Key study will be MAESTRO-NASH, which will have liver biopsy data. Results for this study expecte...
Investors were all spooked today with Dow plummeting more than 500 points. The primary cause can be attributed to inflation fears, disappointing earnings, and booming bond yields. Tech stocks drove the Dow down with the NASDAQ skidding 2.6 percent and the S&P 500 index falling 1.8 percent...
If you're looking for stocks that can add a little excitement to your portfolio, biotech is a great place to start. Clinical-trial results and other binary events regularly send drugmaker stocks surging higher or lower overnight. If you're not sure where to start looking, you're not alo...
This January is going to be a big month for folks with fatty liver disease or need of a COVID-19 vaccine. It's also going to be a month of ups or downs for shareholders of some volatile biotech stocks. Intercept Pharmaceuticals (NASDAQ: ICPT) and Madrigal Pharmaceuticals (...
NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that top-line data from its Phas...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we’re diving into some top candidates! Source: Shutterstock We’re pulling our short stock data from Twi...
After ~14.9% decline on Thursday, Intercept Pharmaceuticals (ICPT -2.6%) continues to trade lower as investors weigh its decision to withdraw the European marketing application for obeticholic acid (OCA) in liver fibrosis due to nonalcoholic steatohepatitis (NASH). The company said that ...
Intercept Pharmaceuticals (NASDAQ:ICPT) has lost ~9.3% in the pre-market after the company announced that it notified the European drug regulator of its decision to withdraw the Marketing Authorization Application (MAA) for obeticholic acid (OCA). With the MAA submitted to the Europ...
The small cap biotech space offers a powerful dimension for active investors because it is comprised of stocks with little or no consistent correlation with the broad market, creating diversification without sacrificing explosive upside potential. But the group is best handled in baskets. In ...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...